This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Mustafa A , Gupta S , Hudes GR , Egleston BL , Uzzo RG , Kruger WD
Serum Amino Acid Levels as a Biomarker for Renal Cell Carcinoma
Journal of Urology. 2011 Oct;186(4) :1206-1212
PMID: WOS:000295399500009 PMCID: PMC3180900
AbstractPurpose: Prognosis in renal cell carcinoma is dependent on tumor stage at presentation, with significant differences in survival between early and late stage disease. Currently to our knowledge no screening tests or biomarkers have been identified for the early detection of kidney cancer. Therefore, we investigated whether serum amino acid profiles are a potentially useful biomarker in patients with renal cell carcinoma. Materials and Methods: The concentrations of 26 amino acids were determined in serum taken preoperatively from 189 patients with renal cell carcinoma, and from 104 age and sex matched controls. Results: Statistically significant changes were observed in patient levels of 15 amino acids, with 13 being decreased and 2 being increased. A logistic regression model using 8 amino acids including cysteine, ornithine, histidine, leucine, tyrosine, proline, valine and lysine was created to distinguish cases from controls. A receiver operator curve based on this model had an area under the curve of 0.81. This same model also had predictive value in terms of overall survival and tumor recurrence in patients with renal cell carcinoma. Conclusions: Our findings suggest that serum amino acid levels may be useful as a screening tool for the identification of individuals with renal cell carcinoma and the prediction of outcomes.
NotesMustafa, Aladdin Gupta, Sapna Hudes, Gary R. Egleston, Brian L. Uzzo, Robert G. Kruger, Warren D. Fox Chase Cancer Center; National Institutes of Health[CA06927]; Commonwealth of Pennsylvania Supported by the Fox Chase Cancer Center Keystone Program in Personalized Kidney Cancer Therapy, National Institutes of Health Core Grant CA06927 and an appropriation from the Commonwealth of Pennsylvania to Fox Chase Cancer Center. 14 Elsevier science inc New york 827be